- Home
- CDRE vs SNDX Comparison
CDRE vs SNDX Comparison
Compare CDRE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- SNDX
- Stock Information
- Founded
- CDRE 2012
- SNDX 2005
- Country
- CDRE United States
- SNDX United States
- Employees
- CDRE N/A
- SNDX N/A
- Industry
- CDRE Industrial Specialties
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- SNDX Health Care
- Exchange
- CDRE Nasdaq
- SNDX Nasdaq
- Market Cap
- CDRE 1.3B
- SNDX 1.1B
- IPO Year
- CDRE 2021
- SNDX 2016
- Fundamental
- Price
- CDRE $31.96
- SNDX $17.04
- Analyst Decision
- CDRE Buy
- SNDX Strong Buy
- Analyst Count
- CDRE 2
- SNDX 10
- Target Price
- CDRE $31.50
- SNDX $37.40
- AVG Volume (30 Days)
- CDRE 319.9K
- SNDX 2.4M
- Earning Date
- CDRE 08-05-2025
- SNDX 11-04-2025
- Dividend Yield
- CDRE 1.18%
- SNDX N/A
- EPS Growth
- CDRE N/A
- SNDX N/A
- EPS
- CDRE 0.93
- SNDX N/A
- Revenue
- CDRE $572,607,000.00
- SNDX $77,933,000.00
- Revenue This Year
- CDRE $12.55
- SNDX $585.73
- Revenue Next Year
- CDRE $7.57
- SNDX $94.17
- P/E Ratio
- CDRE $34.67
- SNDX N/A
- Revenue Growth
- CDRE 7.66
- SNDX 2126.66
- 52 Week Low
- CDRE $27.07
- SNDX $8.58
- 52 Week High
- CDRE $40.28
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- CDRE 55.82
- SNDX 77.37
- Support Level
- CDRE $30.24
- SNDX $15.81
- Resistance Level
- CDRE $31.26
- SNDX $16.89
- Average True Range (ATR)
- CDRE 0.82
- SNDX 0.74
- MACD
- CDRE 0.29
- SNDX -0.06
- Stochastic Oscillator
- CDRE 86.83
- SNDX 89.74
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.